Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

HLX26

Generic Name: HLX26

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

Phase 2

Recruiting

Posted: 2023/03/28

Sponsor:

Shanghai Henlius Bio...

ID:NCT05787613

Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC

Phase 2

Terminated

Posted: 2022/10/18

Sponsor:

Shanghai Henlius Bio...

ID:NCT05584137

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

Phase 1

Completed

Posted: 2022/06/01

Sponsor:

Shanghai Henlius Bio...

ID:NCT05400265

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma

Phase 1

Completed

Posted: 2021/10/14

Sponsor:

Shanghai Henlius Bio...

ID:NCT05078593

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy

Drug Development Updates

HLX26

Overview

Background

Indication

Associated Conditions

Clinical Trials

FDA Approved Products

Singapore Approved Products

Related News

LAG-3 Inhibitors Show Promise in Cancer Immunotherapy, Market Expected to Surge

Drug Development Updates